Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 in Advanced Gynecologic Tumors
NCT04836663Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in endometrial cancer (EC), Cervical Cancer (CC), ovarian cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQ-B3525
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)ovarian cancer
Beyond the preview
Go deeper on NCT04836663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836663.